DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. Alkermes Announces Appointment o ...

In the latest trading session, Alkermes (ALKS) closed at $29.69, marking a -0.37% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.52%. On the other hand, the Dow registered a gain of 0.12%, and the technology-centric Nasdaq increased by 0.9%.The drugmaker's stock has climbed by 10.17% in the past month, exceeding the Medical sector's gain of 5.15% and the S&P 500's gain of 3.85%.Analysts and investors alike will be keeping a close eye on the performance of Alkermes ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.W ...

Biotech stocks are often at the forefront of innovation. These are the companies we hear about that are driving breakthroughs in healthcare. Essentially, they are responsible for improving current treatments by placing a large portion of their earnings back into research. Many people imagine these companies as quite risky, as a result, since many don’t have proven earnings. However, because of the large amount of spending back into the business, they offer explosive growth. With AI being all we practically ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores.What ar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35299 ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 98-1007018 (State or other juri ...

Fourth Quarter and Year-End 2023 Financial Results & Business Update Forward-Looking Statements Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc’s (the “Company”) expectations with respect to its current and future financial and operating performance, business plans or prospects, including its expected cash generat ...

Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Conference Call February 15, 2024 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President, Corporate Affairs and Investor Relations Richard Pops - Chairman and Chief Executive Officer Todd Nichols - Senior Vice President and Chief Commercial Officer Blair Jackson - Executive Vice President and Chief Operating Officer Conference Call Participants David Amsellem - Piper Sandler Akash Tiwari - Jefferies Paul Matteis - Stifel Jason Gerberry - Bank of Ame ...

Alkermes plc (ALKS) reported fourth-quarter 2023 adjusted earnings of 48 cents per share, which beat the Zacks Consensus Estimate of 46 cents. The company had reported adjusted earnings of 40 cents per share in the year-ago quarter.ALKS’ revenues of $377.5 million surged almost 24% from the year-ago quarter’s level owing to strong performance of its proprietary products portfolio. The top line also beat the Zacks Consensus Estimate of $361.2 million.Quarter in DetailALKS derives revenues on net sales of its ...

For the quarter ended December 2023, Alkermes (ALKS) reported revenue of $377.48 million, up 23.9% over the same period last year. EPS came in at $0.48, compared to $0.14 in the year-ago quarter.The reported revenue represents a surprise of +4.50% over the Zacks Consensus Estimate of $361.24 million. With the consensus EPS estimate being $0.46, the EPS surprise was +4.35%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street e ...